<DOC>
	<DOCNO>NCT00440297</DOCNO>
	<brief_summary>To describe immunogenicity safety modify process hepatitis B vaccine administer renal predialysis dialysis patient</brief_summary>
	<brief_title>Hepatitis B Vaccine Predialysis/Dialysis Study ( V232-060 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject least 18 year age Laboratory confirm negative serology result HbsAg ( hepatitis b virus ) , antiHBs ( antibody hepatitis B surface antigen ) , anti HBc ( antibody hepatitis B core antigen ) within 6 week initial dose study vaccine Patient renal dialysis predialysis patient creatinine clearance &lt; =30 ml/min Previous hepatitis B infection , vaccination hepatitis B vaccine Recent febrile illness ; hypersensitivity component license hepatitis B vaccine Recent administration immune globulin , license inactivated vaccine within 14 day license live vaccine within 30 day prior receipt first study vaccine Receipt investigational drug investigational vaccine within 3 month prior Impairment immunologic function Recent use systemic immunomodulatory medication Pregnant woman , nurse mother woman plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hepatitis B virus</keyword>
</DOC>